Efficacy of helicobacter pylori eradication therapy on functional dyspepsia: A meta-analysis of randomized controlled studies with 12-month follow-up

Journal of Clinical Gastroenterology

Volumn 48, Issue 3, 2014, Pages 241-247

  Zhao, Bing ^a   Zhao, Jing ^b   Cheng, Wen Fang ^b   Shi, Wei Jia ^b   Liu, Wei ^b   Pan, Xiao Lin ^b   Zhang, Guo Xin ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Functional dyspepsia; Helicobacter pylori eradication; Meta analysis

Indexed keywords

ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; DYSPEPSIA; EUROPEAN CONTINENTAL ANCESTRY GROUP; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894040259     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31829f2e25     Document Type: Article

References (48)

1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466-1479.
2. Heatley RV, Rathborne BJ. Dyspepsia: A dilemma for doctors? Lancet. 1987;332:779-781.
3. Jones RH, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut. 1990;31:401-405.
4. Shah SS, Bhatia SJ, Mistry FP. Epidemiology of dyspepsia in the general population in Mumbai. Indian J Gastroenterol. 2001;20:103-106.
5. Hirakawa K, Adachi K, Amano K, et al. Prevalence of nonulcer dyspepsia in the Japanese population. J Gastroenterol Hepatol. 1999;14:1083-1087.
6. Kawamura A, Adachi K, Takashima T, et al. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol. 2001;16:384-388.
7. Jeong JJ, Choi MG, Cho YS, et al. Chronic gastrointestinal symptoms and quality of life in the Korean population. World J Gastroenterol. 2008;14:6388-6394.
8. Mertz H, Fullerton S, Naliboff B, et al. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut. 1998;42:814-822.
9. Rosenstock S, Kay L, Rosenstock C, et al. Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes. Gut. 1997;41:169-176.
10. Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solidphase gastric emptying in functional dyspepsia: A metaanalysis. Dig Dis Sci. 1998;43:2028-2033.
11. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346-1352.
12. Leahy A, Besherdas K, Clayman C, et al. Abnormalities of the electrogastrogram in functional gastrointestinal disorders. Am J Gastroenterol. 1999;94:1023-1028.
13. Koch KL, Hong SP, Xu L. Reproducibility of gastric myoelectrical activity and the water load test in patients with dysmotility-like dyspepsia symptoms and in control subjects. J Clin Gastroenterol. 2000;31:125-129.
14. WHO IARC. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the evaluation of carcinogenic risks to humans. Lyon, June 7-14, 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
15. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol. 1996;31:38-47.
16. Strauss RM, Wang TC, Kelsey PB, et al. Association of Helicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am J Med. 1990;89:464-469.
17. Schubert TT, Schubert AB, Ma CK. Symptoms, gastritis, and Helicobacter pylori in patients referred for endoscopy. Gastrointest Endosc. 1992;38:357-360.
18. Nandurkar S, Talley NJ, Xia H, et al. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med. 1998;158:1427-1433.
19. Parente F, Imbesi V, Maconi G, et al. Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. Scand J Gastroenterol. 1998;33:461-467.
20. McColl K, Murray L, EL-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339:1869-1874.
21. Talley NJ, Vakil N, Ballard ED II, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999;341:1106-1111.
22. Koskenpato J, Farkkila M, Sipponen P. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. Am J Gastroenterol. 2001;96:2866-2872.
23. Pih s, Lai KH, Tseng HH, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther. 2001;15:195-201.
24. Bruley DV, Fléjou JF, Colin R, et al. There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 2001;15:1177-1185.
25. Veldhuyzen SJO, Talley NJ, Blum AL, et al. Combined analysis of the ORCHID and OCAY studies: Does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms? Gut. 2002;50:26-30.
26. Koelz HR, Arnold R, Stolte M, et al. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: A double blind randomized trial with a six month follow up. Gut. 2003;52:40-46.
27. Veldhuyzen S, Fedorak RN, Lambert J, et al. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol. 2003;98:1963-1969.
28. Gisbert JP, Cruzado AI, Garcia-Gravalos R, et al. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one year follow-up study. Hepotogastroenterology. 2004;51:303-308.
29. Mazzoleni LE, Sander GB, Ott EA, et al. Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: Results of a 12-month randomized, double blind, placebo-controlled study. Dig Dis Sci. 2006;51:89-98.
30. Tiing LA, Kwong MF, Eng KT, et al. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: A randomized, double blind study. J Gastroenterol. 2006;41:647-653.
31. Kok AG, Leyan T, Reuben KM, et al. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2009;21:417-424.
32. Lan L, Yu J, Chen YL, et al. Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol. 2011;17:3242-3247.
33. Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trail. Arch Intern Med. 2011;171:1929-1936.
34. Gisbert JP, Calvet X, Gabriel R, et al. Helicobacter pylori infection and functional dyspepsia. Meta-Analysis of efficacy of eradication therapy. Med Clin (Barc). 2002;118:405-409.
35. Jin X, Li YM. Systematic review and meta-Analysis from Chinese literature: The association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter. 2007;12:54-56.
36. David M, Alessandro L, Jennifer T, et al. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. Open Med. 2009;3:123-130.
37. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12.
38. Veldhuyzen SJO, KMAJ Tytgat, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol. 1993;46:273-279.
39. Marcelo LR, Anita PO, Benvengo YH, et al. Clinical relevance of the cag A, vacA and iceA genotypes of Helicobacter pylori in Brazilian clinical isolates. FEMS Immunol Med Microbiol. 2003;36:181-185.
40. Daniela B, Carlo FZ, Darren PL, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology. 2008;135:91-99.
41. Loffeld RJ, Werdmuller BF, Kusters JG, et al. Functional dyspepsia is associated with cagA-positive Helicobacter pylori strains. Scand J Gastroenterol. 2001;36:351-355.
42. McColl KE. Helicobacter pylori and acid secretion: Where are we now? Eur J Gastroenterol Hepatol. 1997;9:333-335.
43. Suzuki H, Masaoka T, Sakai G, et al. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol. 2005;20:1652-1660.
44. Harvey RF, Lane JA, Nair P, et al. Clinical trial: Prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations-The Bristol Helicobacter Project. Aliment Pharmacol Ther. 2010;32:394-400.
45. Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy. Gastroenterol Res Pract. 2012;10:1155-1164.
46. Sang PY, Han GS, Chang SO, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452-456.
47. Jyh ML, Chieh CC, Mei JC, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomized trial. Lancet. 2012; 381:205-213.
48. Laheij RJ, Jansen JB, Van de Lisdonk EH, et al. Review article: Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther. 1996;10:843-850.